Kyowa Kirin Co., Ltd.
4151
Classificação em ações
#2445
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Preço da ação
$15.32
Valor de mercado
$8.02B
Variação (1 dia)
0.88%
Variação (1 ano)
2.20%
País
JP
Negociar Kyowa Kirin Co., Ltd. (4151)
Categoria
Healthcare
Rácio P/E de Kyowa Kirin Co., Ltd. (4151)
Rácio P/E em October 2026 TTM: 14.82
De acordo com os últimos relatórios financeiros e o preço das ações da Kyowa Kirin Co., Ltd., o rácio P/E atual (TTM) é 14.82. No final de 2024, a empresa tinha um P/E de 21.01.
Histórico do rácio P/E da Kyowa Kirin Co., Ltd. de 2001 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 14.82 | -24.91% |
| 2025 | 19.73 | -6.09% |
| 2024 | 21.01 | 33.89% |
| 2023 | 15.69 | -48.20% |
| 2022 | 30.30 | -5.84% |
| 2021 | 32.18 | 0.12% |
| 2020 | 32.14 | -12.62% |
| 2019 | 36.78 | 78.93% |
| 2018 | 20.56 | -26.05% |
| 2017 | 27.80 | -41.32% |
| 2016 | 47.37 | 34.58% |
| 2015 | 35.20 | -10.00% |
| 2014 | 39.11 | 85.42% |
| 2013 | 21.09 | 9.62% |
| 2012 | 19.24 | -7.75% |
| 2011 | 20.86 | -2.79% |
| 2010 | 21.46 | -66.44% |
| 2009 | 63.93 | 296.39% |
| 2008 | 16.13 | -53.66% |
| 2007 | 34.80 | 55.70% |
| 2006 | 22.35 | 14.16% |
| 2005 | 19.58 | -34.03% |
| 2004 | 29.68 | 14.74% |
| 2003 | 25.87 | -52.36% |
| 2002 | 54.29 | 46.46% |
| 2001 | 37.07 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 40.53 | 173.56% |
US
|
|
| 38.50 | 159.84% |
US
|
|
| 79.88 | 439.15% |
US
|
|
| 116.96 | 689.43% |
US
|
|
| 22.25 | 50.17% |
CH
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.